Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | LTK | P29376 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18264172 | 0.81 | PIM1 (0.43) | CHEK1FLT3PLK3GAAALDH1A1 | |
| SCHEMBL18264146 | 0.79 | ACHE (0.40) | CHEK1FLT3PLK3CDK5CLK4 | |
| SCHEMBL18264155 | 0.79 | HTT (0.51) | CHEK1FLT3PLK3GAAPDPK1 | |
| SCHEMBL18264159 | 0.77 | MAPT (0.52) | KDRGAAKDM4EALDH1A1HPGD | |
| SCHEMBL18264402 | 0.76 | EGFR (0.47) | CDK5CLK4DYRK1BMAP4K4CSF1R | |
| SCHEMBL18264153 | 0.76 | CHEK1 (0.47) | CHEK1FLT3PLK3CDK5CLK4 | |
| SCHEMBL1894901 | 0.74 | KMT2A (0.44) | CDK5GAAKDM4ECYP3A4NOS1 | |
| SCHEMBL18264175 | 0.74 | KDM1A (0.52) | CDK5CLK4DYRK1BMAP4K4CSF1R | |
| SCHEMBL25414580 | 0.73 | APP (0.43) | CDK5CLK4DYRK1BMAP4K4CSF1R | |
| SCHEMBL1162693 | 0.72 | BTK (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302060-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | Kaohsiung Medical University (TW) | 2018-04-11 | — | — | EP | claimed |
| WO-2016191576-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE | DCB-USA LLC (US) | 2016-12-01 | — | — | WO | claimed |
| EP-3662751-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2021-10-13 | — | — | EP | disclosed |
| US-11135206-B2 | Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-10-05 | — | — | US | disclosed |
| US-11135206-B2 | Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-10-05 | — | — | US | disclosed |
| US-11052072-B2 | Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-07-06 | — | — | US | disclosed |
| EP-3662751-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE | Kaohsiung Medical University (TW) | 2020-06-10 | — | — | EP | disclosed |
| US-20200113878-A1 | PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2020-04-16 | — | — | US | disclosed |
| EP-3302060-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2020-02-12 | — | — | EP | disclosed |
| EP-3302060-B1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | UNIV KAOHSIUNG MEDICAL (TW) | 2020-02-12 | — | — | EP | disclosed |
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | disclosed |
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | disclosed |
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-08-02 | — | — | US | disclosed |
| EP-3302060-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | Kaohsiung Medical University (TW) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191576-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE | DCB-USA LLC (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016191576-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE | DCB-USA LLC (US) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214426-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE | UGT1A3, UGT1A1, GUSB | CHEK1 669/4885FLT3 696/4885PLK3 783/4885 |
| US-20200113878-A1 | PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase | UGT1A3, UGT1A1, GUSB | CHEK1 669/4885FLT3 696/4885PLK3 783/4885 |
| US-11052072-B2 | Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase | UGT1A3, UGT1A1, DPP3 | CHEK1 659/4885FLT3 626/4885PLK3 837/4885 |
| US-11135206-B2 | Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase | UGT1A3, UGT1A1, DPP3 | CHEK1 659/4885FLT3 626/4885PLK3 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.